Clover Health Investments, Corp vs Pfizer, Inc. — Stock Comparison
Clover Health Investments, Corp (CLOV) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Pfizer, Inc. clearly outscores Clover Health Investments, Corp on Q·Score (6.4 vs 4.5 out of 10), led by Valuation (7.7 vs 2.9) and Quality (6.4 vs 3.1). Clover Health Investments, Corp scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for PFE (+15.8%) than for CLOV (-17.0%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Revenue expanding at 62% year-over-year.
⚠ consensus analyst target is below current price.
Forward P/E of 8.9× is low relative to sector peers.
⚠ earnings contracting 10% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
CLOV vs PFE: which stock scores better overall?
Based on Q·Score, Pfizer, Inc. (PFE) scores 6.4/10 versus Clover Health Investments, Corp (CLOV) at 4.5/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: CLOV or PFE?
Clover Health Investments, Corp (CLOV) scores higher on Growth (6.9/10 vs 5.1/10). Clover Health Investments, Corp reports revenue growth (62.0% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is CLOV or PFE more attractively valued?
Pfizer, Inc. (PFE) scores higher on Valuation (7.7/10 vs 2.9/10). CLOV trades at 50.0× P/E versus PFE at 8.9×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about CLOV vs PFE?
There are 3 analysts covering CLOV with a consensus price target of $4.15, and 27 analysts covering PFE with a consensus target of $29.19. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: CLOV or PFE?
Pfizer, Inc. (PFE) scores higher on Quality (6.4/10 vs 3.1/10). Net profit margin: CLOV at -2.6%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: CLOV or PFE?
Pfizer, Inc. (PFE) scores higher on Financial Health (7/10 vs 5.5/10). Market beta: CLOV at 2.48, PFE at 0.29. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of CLOV and PFE?
Clover Health Investments, Corp (CLOV) has a market capitalisation of $2.6B, while Pfizer, Inc. (PFE) has a market cap of $143.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do CLOV or PFE pay dividends?
CLOV does not currently pay a dividend, while PFE pays a dividend yield of 6.82%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →